FeesSafety
Pluang+

Intellia Therapeutics gains as FDA grants Priority Review for HAE treatment and analyst hikes price target.

Analyst Insights
09 Sep 2026, 21:14 WIB
Stuart Mooney
View Source
Bullish
Intellia Therapeutics gains as FDA grants Priority Review for HAE treatment and analyst hikes price target.

Intellia Therapeutics saw a boost after Wedbush analyst raised its price target to $13, signaling potential upside from its current $12.64 share price. The FDA granted Priority Review to Intellia's lonvo-z treatment for Hereditary Angioedema, with a decision expected by March 10, 2027. The company also secured a $400 million non-dilutive loan to support the potential U.S. launch of lonvo-z, underscoring confidence in its gene-editing technology and growth prospects in precision medicine.

More News

Monday.com expands AI platform; Okta leads in identity security with strong 2026 results.

Monday.com expands AI platform; Okta leads in identity security with strong 2026 results.

Monday.com is growing its AI-driven platform beyond work management into CRM and software development, achieving 22.4% revenue growth and nearly $1.4 billion in revenue for the year ending September 2026. Okta, a leader in identity security, serves o...

Market News
Neutral
44 minutes ago
Invest long-term and avoid market timing to maximize returns, inspired by Wayne Gretzky's advice.

Invest long-term and avoid market timing to maximize returns, inspired by Wayne Gretzky's advice.

Warren Buffett highlights Wayne Gretzky's famous advice, "Skate to where the puck is going to be," as a key investing lesson: focus on the future and stay invested long-term. Fidelity research shows missing the five best days in the S&P 500 from 1987...

Market News
Bullish
1 hour ago
New AI tool checks stock filings for hidden warning signs to aid investors' decisions.

New AI tool checks stock filings for hidden warning signs to aid investors' decisions.

A new AI-powered prompt helps investors identify warning signs in company filings by scanning for issues like auditor doubts, insider sales, and leadership changes. It highlights items worth closer inspection without giving investment advice, using r...

Market News
Bearish
1 hour ago
Netflix's stock drops nearly 47% but remains profitable with growth potential over five years.

Netflix's stock drops nearly 47% but remains profitable with growth potential over five years.

Netflix's shares have fallen nearly 47% from their 52-week high, reflecting concerns about slowing revenue growth and increased competition. Despite this, Netflix remains highly profitable, with rising operating margins and expected revenue growth of...

Market News
Neutral
1 hour ago
Tesla ends Cybertruck production, boosting Rivian's chance to capture electric truck buyers.

Tesla ends Cybertruck production, boosting Rivian's chance to capture electric truck buyers.

Tesla is ending production of its Cybertruck to focus on other projects, leading to increased demand for alternative electric trucks. Rivian, with its newly launched lower-cost R2 model, is well-positioned to attract former Cybertruck customers. This...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App